February 6, 2018 / 12:03 PM / 16 days ago

BRIEF-Allergan Announces Positive Phase 3 Results For Ubrogepant

Feb 6 (Reuters) - Allergan Plc:

* ALLERGAN ANNOUNCES POSITIVE TOP LINE PHASE 3 RESULTS FOR UBROGEPANT - AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE

* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES

* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES

* RESULTS OF SECOND PHASE 3 TRIAL, ACHIEVE II (UBR-MD-02), ARE EXPECTED IN 1ST HALF OF 2018

* ALLERGAN - ANTICIPATES FILING NDA TO FDA FOR ACUTE MIGRAINE TREATMENT DRUG IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below